Farnesoid X receptor agonists and uses thereof

1. A compound of Formula (IV), or a pharmaceutically acceptable salt or solvate thereof:

wherein:

R 1 and R 2 are each independently selected from H, D, F, C 1 -C 4 alkyl, and C 1 -C 4 fluoroalkyl;

ring A is a monocyclic carbocycle;

each R A is independently selected from H, D, halogen, —CN, —OH, —OR 10 , —SR 10 , —S(═O)R 11 , —S(═O) 2 R 11 , —NHS(═O) 2 R 11 , —S(═O) 2 N(R 10 ) 2 , —C(═O)R 11 , —OC(═O)R 11 , —CO 2 R 10 , —OCO 2 R 11 , —C(═O)N(R 10 ) 2 , —OC(═O)N(R 10 ) 2 , —NR 10 C(═O)N(R 10 ) 2 , —NR 10 C(═O)R 11 , —NR 10 C(═O)OR 11 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 2 -C 6 alkenyl, substituted or unsubstituted C 2 -C 6 alkynyl, substituted or unsubstituted C 1 -C 6 fluoroalkyl, and substituted or unsubstituted C 1 -C 6 heteroalkyl;

ring B is a bicyclic heterocycle;

each R B is independently selected from H, D, halogen, —CN, —OH, —OR 10 , —SR 10 , —S(═O)R11, —S(═O) 2 R11, —N(R 10 ) 2 , —NHS(═O) 2 R 11 , —S(═O) 2 N(R 10 ) 2 , —C(═O)R 11 , —OC(═O)R 11 , —CO 2 R 10 , —OCO 2 R 11 , —C(═O)N(R 10 ) 2 , —OC(═O)N(R 10 2 , —NR 10 C(═O)N(R 10 ) 2 , —NR 10 C(═O)R 11 , —NR 10 C(═O)OR 11 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 2 -C 6 alkenyl, substituted or unsubstituted C 2 -C 6 alkynyl, substituted or unsubstituted C 1 -C 6 fluoroalkyl, and substituted or unsubstituted C 1 -C 6 heteroalkyl;

R 3 is selected from substituted or unsubstituted C 1 -C 10 alkyl, or substituted or unsubstituted C 3 -C 10 cycloalkyl, wherein if R 3 is substituted then R 3 is substituted with one or more R 12 groups;

each R 12 is independently selected from D, halogen, —CN, —NO 2 , —OR 10 , —SR 10 , —S(═O)R 11 , —S(═O) 2 R 11 , —S(═O) 2 N(R 10 ) 2 , —NR 10 S(═O) 2 R 11 , —C(═O)R 11 , —OC(═O)R 11 , —CO 2 R 10 , —OCO 2 R 11 , —N(R 10 ) 2 , —C(═O)N(R 10 ) 2 , —OC(═O)N(R 10 ) 2 , —NR 10 C(═O)R 11 , —NR 10 C(═O)OR 11 , unsubstituted or substituted C 1 -C 10 alkyl, unsubstituted or substituted C 1 -C 10 fluoroalkyl, unsubstituted or substituted C 2 -C 10 alkenyl, unsubstituted or substituted C 2 -C 10 alkynyl, unsubstituted or substituted C 1 -C 10 heteroalkyl, and unsubstituted or substituted C 3 -C 10 cycloalkyl;

R 4 is absent or -L 3 -Y;

L 3 is absent, —C(R 5 )(R 6 )—, —C(R 5 )(R 6 )—C(R 7 )(R 8 )—, —O—C(R 7 )(R 8 )—, or —C(R 5 )(R 6 )—O—;

R 5 and R 7 are each independently selected from H, D, C 1 -C 4 alkyl and C 3 -C 6 cycloalkyl;

or R 5 and R 7 are taken together with the intervening atoms to form a double bond;

or R 5 and R 7 are taken together with the intervening atoms to form an epoxide or a substituted or unsubstituted C 3 -C 6 cycloalkyl;

R 6 and R 8 are each independently selected from H, D, C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl;

Y is -CH 2 OR 9 , -C(═O)OR 9 ,

R 9 is selected from H, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted C 2 -C 6 alkenyl, substituted or unsubstituted C 3 -C 6 cycloalkyl, substituted or unsubstituted phenyl, and substituted or unsubstituted heterocycle;

L 1 is absent;

ring C is phenyl, bicyclic carbocycle, monocyclic 6-membered heteroaryl containing 1-3 N atoms, or bicyclic heterocycle;

each R C is independently selected from H, D, halogen, —CN, —OH, —OR 10 , —S(═O)R 11 , —NO 2 , —N(R 10 ) 2 , —S(═O) 2 R 11 , —NHS(═O) 2 R 11 , —S(═O) 2 N(R 10 ) 2 , —C(═O)R 11 , —OC(═O)R 11 , —CO 2 R 10 , —OCO 2 R 11 , —C(═O)N(R 10 ) 2 , —OC(═O)N(R 10 ) 2 , —NR 10 C(═O)N(R 10 ) 2 , —NR 10 C(═O)R 11 , —NR 10 (═O)OR 11 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 2 -C 6 alkenyl, substituted or unsubstituted C 2 -C 6 alkynyl, substituted or unsubstituted C 1 -C 6 fluoroalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted phenyl, and substituted or unsubstituted monocyclic heteroaryl;

each R 10 is independently selected from H, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 fluoroalkyl, and substituted or unsubstituted C 3 -C 6 cycloalkyl;

or two R 10 on the same N atom are taken together with the N atom to which they are attached to form a N-containing heterocycle;

each R 11 is independently selected from substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted C 1 -C 6 fluoroalkyl, substituted or unsubstituted C 3 -C 6 cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted monocyclic heteroaryl, and substituted or unsubstituted benzyl;

m is 0, 1, or 2;

n is 0, 1, or 2; and

p is 0, 1, 2, 3, or 4;

wherein any substituted group is substituted with one or more groups individually and independently selected from D, halogen, —CN, —NH 2 , —NH(CH 3 ), —N(CH 1 ) 2 —OH, —CO 2 H, —CO 2 ( C 1 -C 4 alkyl), —C(═O)NH 2 , —C(═O)NH(C 1 -C 4 alkyl), —C(═O)N(C 1 -C 4 alkyl) 2 , —S(═O) 2 NH 2 , —S(═O) 2 NH(C 1 -C 4 alkyl), —S(═O) 2 N(C 1 -C 4 alkyl) 2 , C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 fluoroalkyl, C 1 -C 4 heteroalkyl, C 1 -C 4 alkoxy, C 1 -C 4 fluoroalkoxy, —SC 1 -C 4 alkyl, —S(═O)C 1 -C 4 alkyl, and —S(═O) 2 C 1 -C 4 alkyl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein:

ring B is an 8-, 9- or 10-membered bicyclic heterocycle with at least one N atom in the ring.

3. The compound of claim 2 , or a pharmaceutically acceptable salt or solvate thereof, wherein:

4. The compound of claim 2 , or a pharmaceutically acceptable salt or solvate thereof, wherein:

5. The compound of claim 4 , or a pharmaceutically acceptable salt or solvate thereof, wherein:

ring A is phenyl or a monocyclic C 3 -C 8 cycloalkyl that is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

6. The compound of claim 5 , or a pharmaceutically acceptable salt or solvate thereof, wherein:

7. The compound of claim 3 , or a pharmaceutically acceptable salt or solvate thereof, wherein:

ring C is phenyl.

8. The compound of claim 7 , or a pharmaceutically acceptable salt or solvate thereof, wherein:

R 3 is selected from substituted or unsubstituted C 1 -C 10 alkyl, substituted or unsubstituted C 3 -C 10 cycloalkyl, or substituted or unsubstituted aryl, wherein if R 3 is substituted then R 3 is substituted with one or more R 12 groups.

9. The compound of claim 8 , or a pharmaceutically acceptable salt or solvate thereof, wherein:

R 3 is selected from methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, n-pentyl, tert-pentyl, neopentyl, isopentyl, sec-pentyl, 3-pentyl, n-hexyl, isohexyl, 3-methylpentyl, 2,3-dimethylbutyl, neohexyl, substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, and substituted or unsubstituted cyclohexyl.

10. The compound of claim 9 , or a pharmaceutically acceptable salt or solvate thereof, wherein:

R 4 is

11. The compound of claim 10 , or a pharmaceutically acceptable salt or solvate thereof, wherein: R 1 and R 2 are each H.

12. The compound of claim 11 , or a pharmaceutically acceptable salt or solvate thereof, wherein m and n are each 0.

13. The compound of claim 1 , wherein the compound is:

Methyl 7-(N-((4′-(dimethylamino)-[1,1′-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)-1H-indole-2-carboxylate;

Methyl 4-(N-((4′-(dimethylamino)-[1,1′-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)-1H-indole-2-carboxylate;

Methyl 7-(N-((4′-(dimethylamino)-[1,1′-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)-benzo[b]thiophene-2-carboxylate;

Methyl 1-(N-((4′-(dimethylamino)-[1,1′-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)-isoquinoline-6-carboxylate;

Ethyl 8-(N-((4′-(dimethylamino)-[1,1′-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)-quinoline-3-carboxylate;

Methyl 1-(N-((4′-(dimethylamino)-[1,1′-biphenyl]-4-yl)methyl)pivalamido)isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)-isoquinoline-6-carboxylate;

Ethyl 1-(N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)-isoquinoline-6-carboxylate;

Isopropyl 1-(N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)-cyclohexanecarboxamido)isoquinoline-6-carboxylate;

Ethyl 5-(N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)-quinoline-2-carboxylate;

Methyl 1-(N-((3′-cyano-4′-methoxy-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)cycloheptanecarboxamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-((2-cyano-4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)acetamido)isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)isobutyramido)-isoquinoline-6-carboxylate;

Methyl 1-(N-((2′,3′-difluoro-4′-methoxy-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)isoquinoline-6-carboxylate;

Methyl 1-(N-((3′-cyano-4′-methyl-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-((3′-chloro-4′-cyano-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-chloro-3′-cyano-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(3,3-dimethyl-N-(4-(6-(trifluoromethyl)pyridin-3-yl)benzyl)butanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-(4-(2,2-difluorobenzo[d][1,3]dioxo1-5-yl)benzyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-(4-(5-fluoro-6-methoxypyridin-3-yl)benzyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-(4-(5-chloro-6-methoxypyridin-3-yl)benzyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-(4-(6-methoxy-5-methylpyridin-3-yl)benzyl)-3,3-dimethylbutanamido)isoquinoline-6-carboxylate;

Methyl 1-(N-(4-(6-(dimethylamino)pyridin-3-yl)benzyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(3,3-dimethyl-N-(4-(6-methylpyridin-3-yl)benzyl)butanamido)isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-cyclopropyl-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-((3′-chloro-4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-cyano-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-(hydroxymethyl)-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(3,3-dimethyl-N-(4-(1-methyl-1H-indol-5-yl)benzyl)butanamido)isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-methoxy-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-(4-(2,3-dihydrobenzofuran-5-yl)benzyl)-3,3-dimethylbutanamido)isoquinoline-6-carboxylate;

Methyl 1-(N-(4-(2,3-dihydrobenzofuran-6-yl)benzyl)-3,3-dimethylbutanamido)isoquinoline-6-carboxylate;

Methyl 1-(N-(4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)benzyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(3,3-dimethyl-N-(4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)butanamido)-isoquinoline-6-carboxylate;

Methyl 1-(3,3-dimethyl-N-(4-(2-methylbenzo [d]thiazol-5-yl)benzyl)butanamido)isoquinoline-6-carboxylate;

Methyl 1-(N-(4-(1-(tert-butoxycarbonyl)indolin-5-yl)benzyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-ethoxy-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-ethyl-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-fluoro-3′-methoxy-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-((3′-chloro-4′-methyl-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-(difluoromethoxy)-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-(methoxymethyl)-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-(2-methoxyethoxy)-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-(2-hydroxyethoxy)-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-(2-hydroxyethyl)-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-(2-methoxyethyl)[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-(4-(indolin-5-yl)benzyl)-3,3-dimethylbutanamido)isoquinoline-6-carboxylate;

Methyl 1-(3 ,3 -dimethyl-N-(4-(1-methylindolin-5-yl)benzyl)butanamido)isoquinoline-6-carboxylate;

Methyl 1-(trans-4-hydroxy-N-((4′-methoxy-3 ′-methyl-[1,1 ′-biphenyl]-4-yl)methyl)-cyclohexanecarboxamido)isoquinoline-6-carboxylate;

Methyl 1-(trans-N-((3′-chloro-4′-methoxy-[1,1′-biphenyl]-4-yl)methyl)-4-hydroxycyclohexanecarboxamido)isoquinoline-6-carboxylate;

Methyl 1-(trans-N-((3′-cyano-4′-methoxy-[1,1′-biphenyl]-4-yl)methyl)-4-hydroxycyclohexanecarboxamido)isoquinoline-6-carboxylate;

Isopropyl 1-(N-((3′-cyano-4′-methoxy-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)isoquinoline-6-carboxylate;

Isopropyl 1-(N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)-3-methylbutanamido)isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)cyclopentanecarboxamido)-isoquinoline-6-carboxylate;

Methyl 1-(2-cyclopentyl-N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)acetamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)benzamido)isoquinoline-6-carboxylate;

Methyl 1-(2-cyclohexyl-N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)acetamido)-isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)-4,4-dimethylpentanamido)isoquinoline-6-carboxylate;

Methyl 1-(2-cyclobutyl-N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)acetamido)-isoquinoline-6-carboxylate;

Methyl 1-(2-cyclopropyl-N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)acetamido)isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)pentanamido)isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)butyramido)isoquinoline-6-carboxylate;

Methyl 1-(N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)-2-(oxetan-3-yl)acetamido)-isoquinoline-6-carboxylate;

Methyl 1-(3-hydroxy-N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)propanamido)-isoquinoline-6-carboxylate;

Methyl 1-(4-hydroxy-N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)butanamido)-isoquinoline-6-carboxylate;

Methyl 1-(5-hydroxy-N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)pentanamido)-isoquinoline-6-carboxylate;

Isopropyl 1-(N-((trans-4-(4-methoxy-3-methylphenyl)cyclohexyl)methyl)-3,3-dimethylbutanamido)isoquinoline-6-carboxylate;

Isopropyl 1-(N-((trans-4-(4-methoxy-3-methylphenyl)cyclohexyl)methyl)-3,3-dimethylpentanamido)isoquinoline-6-carboxylate;

Methyl 1-(3,3-dimethyl-N-((trans-4-(o -tolyl)cyclohexyl)methyl)butanamido)isoquinoline-6-carboxylate;

Methyl 1-(3,3-dimethyl-N-((trans-4-(m-tolyl)cyclohexyl)methyl)butanamido)isoquinoline-6-carboxylate;

Methyl 1-(3,3-dimethyl-N-((trans-4-(p-tolyl)cyclohexyl)methyl)butanamido)isoquinoline-6-carboxylate;

Methyl 1-(N-((trans-4-(2-methoxyphenyl)cyclohexyl)methyl)-3,3-dimethylbutanamido) -isoquinoline-6-carboxylate;

Methyl 1-(N-((trans-4-(3-methoxyphenyl)cyclohexyl)methyl)-3,3-dimethylbutanamido) -isoquinoline-6-carboxylate;

Methyl 1-(N-((trans-4-(4-methoxyphenyl)cyclohexyl)methyl)-3,3-dimethylbutanamido) -isoquinoline-6-carboxylate;

Methyl 1-(N-((trans-4-(4-chlorophenyl)cyclohexyl)methyl)-3,3-dimethylbutanamido) -isoquinoline-6-carboxylate;

Methyl 1-(N-((trans-4-(4-methoxy-3-methylphenyl)cyclohexyl)methyl)-3,3-dimethylbutanamido)isoquinoline-6-carboxylate;

Methyl 1-(N-((trans-4-(4-methoxy-3-methylphenyl)cyclohexyl)methyl)cyclohexanecarboxamido)isoquinoline-6-carboxylate;

Methyl 1-(trans-4-hydroxy-N-((trans-4-(4-methoxy-3-methylphenyl)cyclohexyl)methyl) -cyclohexanecarboxamido)isoquinoline-6-carboxylate;

1-(N-((trans-4-(4-Methoxy-3-methylphenyl)cyclohexyl)methyl)-3,3-dimethylbutanamido)isoquinoline-6-carboxylic acid;

1-(N-((4′-methoxy-3′-methyl- [1,1 ′-biphenyl]-4-yl)methyl)-3,3 -dimethylbutanamido)-isoquinoline-6-carboxylic acid;

(E)-Methyl 3-(1-(N-((4′-methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido)isoquinolin-6-yl)acrylate;

(E)-3 -(1 -(N-((4′-Methoxy-3′-methyl-[1,1 ′-biphenyl]-4-yl)methyl)-3,3 -dimethylbutanamido)-isoquinolin-6-yl)acrylic acid;

3-(1-(N44′-Methoxy-3′-methyl-[1,1′-biphenyl]-4-yl)methyl)-3,3-dimethylbutanamido) -isoquinolin-6-yl)propanoic acid;

or a pharmaceutically acceptable salt or solvate thereof.

14. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt, or solvate thereof, and at least one pharmaceutically acceptable excipient.

15. A method of treating a liver disease in a subject, comprising administering to the subject a therapeutically effective amount of one or more of the compounds of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein the liver disease is primary biliary cirrhosis, primary sclerosing cholangitis, cholestasis, nonalcoholic steatohepatitis (NASH), or nonalcoholic fatty liver disease (NAFLD).

16. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein:

ring C is bicyclic carbocycle selected from indanyl, indenyl, and naphthyl.

17. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein:

18. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein: